特利加压素的使用与1型肝肾综合征合并慢加急性肝衰竭患者呼吸衰竭的关系
基于CONFIRM研究的事后分析,299例1型肝肾综合征患者按2:1随机接受特利加压素或安慰剂(均联合白蛋白)。特利加压素组3级慢加急性肝衰竭患者呼吸衰竭发生率为30%,显著高于1-2级的9.4%(p=0.0002),且3级患者90天生存率在特利加压素组为27.55%、安慰剂组为50.0%(p=0.122)。作者认为1型肝肾综合征合并3级慢加急性肝衰竭患者应慎用特利加压素,低氧血症患者呼吸衰竭和死亡风险增加。
要点
- 特利加压素组3级慢加急性肝衰竭患者呼吸衰竭发生率为30%,高于1-2级的9.4%(p=0.0002)。
- 安慰剂组3级与1-2级慢加急性肝衰竭患者呼吸衰竭发生率无显著差异(p>0.05)。
- 3级慢加急性肝衰竭患者中,特利加压素组与安慰剂组呼吸衰竭发生率差异显著(p=0.01)。
核心结论
- 作者认为,1型肝肾综合征合并3级慢加急性肝衰竭患者应慎用特利加压素。
- 低氧血症患者发生呼吸衰竭和死亡的风险增加。
研究设计与样本
- CONFIRM研究的事后分析,299例1型肝肾综合征患者按2:1随机接受特利加压素(n=200)或安慰剂(n=99),两组均联合白蛋白。
- 入组时使用经过验证的慢加急性肝衰竭分级系统评估所有患者的器官衰竭。
主要发现
- 特利加压素组呼吸衰竭发生率在1-2级慢加急性肝衰竭患者中为9.4%,在3级患者中为30%(p=0.0002)。
- 安慰剂组呼吸衰竭发生率在1-2级慢加急性肝衰竭患者中为6.2%,在3级患者中为0%(p>0.05)。
- 3级慢加急性肝衰竭患者中,特利加压素组与安慰剂组呼吸衰竭发生率差异显著(p=0.01)。
- 特利加压素组呼吸衰竭的基线预测因素包括INR(p=0.011)、平均动脉压(p=0.037)和SpO2(p=0.014)。
- 既往白蛋白作为连续变量不是呼吸衰竭的预测因素。
临床怎么用
- 作者认为,1型肝肾综合征合并3级慢加急性肝衰竭患者应慎用特利加压素。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Previous studies suggested increased mortality in patients with hepatorenal syndrome type 1 (HRS1) and advanced acute-on-chronic liver failure (ACLF). AIM: To assess mortality and respiratory failure (RF) in patients with HRS1 and ACLF treated with terlipressin. METHODS: In the CONFIRM study, we randomised 299 patients with HRS1 2:1 to terlipressin or placebo, both with albumin. At enrolment, all patients were assessed for organ failure (OF) using a validated ACLF grading system. Post hoc analyses assessed the effects of terlipressin vs. placebo on the incidence of RF and 90-day mortality. RESULTS: The incidence of RF with terlipressin (n = 200) was 9.4% in patients with grades 1-2 ACLF, and 30% with grade 3 ACLF (p = 0.0002); no such difference was observed in placebo-treated patients (n = 99) (6.2% grades 1-2 vs. 0% grade 3 ACLF, p > 0.05). RF incidence between terlipressin and placebo in patients with grade 3 ACLF was significant (p = 0.01). Baseline predictors of RF with terlipressin were INR (p = 0.011), mean arterial pressure (p = 0.037), and SpO2 (p = 0.014). Prior albumin as a continuous variable was not a predictor of RF. 90-day survival between terlipressin and placebo arms was similar for grades 1-2 ACLF (55.5% and 56.6%, respectively), but lower for grade 3 ACLF (27.55% vs. 50.0%) (p = 0.122), mainly related to RF. CONCLUSION: Terlipressin should be used with caution in patients with HRS1 and grade 3 ACLF. Patients with hypoxaemia are at increased risk of RF and mortality.
引用
- Wong F, Pappas SC, Reddy KR, et al. Terlipressin use and respiratory failure in patients with hepatorenal syndrome type 1 and severe acute-on-chronic liver failure. Aliment Pharmacol Ther. 2022. PMID: 35995728. doi:10.1111/apt.17195
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。